investor presentation - nmc...2018/11/05  · 2017 group revenues: usd 1.6bn operations across 17...

47
Investor Presentation November 2018

Upload: others

Post on 03-Jul-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

Investor Presentation

November 2018

Page 2: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

2

Prasanth Manghat

CEO

Hani Buttikhi

CIO

Senior management presenting

Prashanth Shenoy

CFO

2

Asjad Yahya

Investor Relations

Page 3: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

3

Agenda

3

1 Overview of the business

3 Transformational partnership with GOSI to form a new KSA healthcare champion

4 M&A: A vital part of the story

6 Financial outlook

7 Appendix A: A closer look at key assets

8 Appendix B: Snapshot of UAE healthcare market

5 Developing a dedicated International Patient Center

2 Understanding the Saudi opportunity better

Page 4: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

4

NMC at a glance

4

Over 113,000

distribution SKUs

100+ owned and managed facilities

2017 Group revenues:

USD 1.6bn

Operations across

17 countries

Over 5.7 mnpatients in 2017

2,186licensed beds

2017 Group EBITDA:

USD 353mn

20%

2017 RoAE

FTSE 100 company

c. £7bn market cap

c. 2,000 doctors

c. 20,000 staff

Page 5: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

5

Est. 1975

c.109,000 SKU’s

Five verticals built around centres of excellence

5

CENTRE OF

EXCELLENCE

Est. 1975

1,526 beds

Est. 2015

106 beds & c.20k Cycles

Est. 2015

554 beds

Est. 2012

Over 1,000 beds

Card

iolo

gyL

ong-te

rm

Care

Page 6: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

6

Future growth driven by a well-defined strategy

6

2015 Strategy Update 2017 Strategy Update

Capacity Build Capabilities Focus Geographic Expansion

Accelerate the establishment of Centres of Excellence in

key specialties within existing hospitalsAddition of new verticals focused on highly

underserved segments in the UAE and wider GCC and

further development of Centres of Excellence

Establish a strategic presence outside the UAE with

leading global medical institutions to enhance and

expand technological know-how and medical expertise

Increase participation in the growing UAE medical

tourism industry and establish NMC as a destination of

choice

Grow NMC’s medical speciality offering and clinic

network within the UAE and maximising operational

synergies

Increase NMC’s footprint in Saudi Arabia and the

broader GCC via organic initiatives and acquisitions

NMC Health’s strategy is built on three key tenets

Expanding the healthcare business’ target market

from the GCC to wider emerging markets

Fertility to be developed as a global business taking

advantage of substantial growth opportunities

Rapid adoption and deployment of technological

innovation via both organic initiatives and acquisitions

1 2 3

Page 7: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

77

An expansive footprint: 100+ facilities across 17 countries

Own and O & M

Key to facilities

Own

O & M

Colombia

Brazil

Spain

UK

Sweden

Kenya

YemenOmanUnited Arab Emirates

Italy

Latvia

Slovakia

Egypt

Denmark

Kuwait

Saudi Arabia

Jordan

Page 8: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

8

Benefitting from attractive underlying dynamics in core markets

Abu Dhabi: A case

study on impact of

mandatory

insurance roll-out

UAE market still has

potential for

considerable

growth

GCC as a whole

offers even bigger

growth potential

Population Insured population Incidences

2mn

3mn

2007 2014

1mn

3mn

2007 2014

3.5mn

24mn

2007 2014

+2X8per capita incidence rate in

Abu Dhabi in 2014

75mnincidences in

next 5 years

6-7per capita incidence assumed

+3X8

per capita incidence rate in

Abu Dhabi in 2014

275mnincidences in GCC

in next 7 years

5per capita incidence assumed

Roll-out of mandatory insurance remains the biggest tailwind for the healthcare sector in the region

Please note: The above analysis has been complied for illustration purposes only and is based on NMC’s own estimates and projections and should not be taken as factual data or relied

upon

Page 9: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

9

Agenda

9

2

1

Understanding the Saudi opportunity better

Overview of the business

3 Transformational partnership with GOSI to form a new KSA healthcare champion

4 M&A: A vital part of the story

6 Financial outlook

7 Appendix A: A closer look at key assets

8 Appendix B: Snapshot of UAE healthcare market

5 Developing a dedicated International Patient Center

Page 10: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

10

Attractive demographics working in NMC’s favour

10

33m pop’n

▪ 2% growth rate p.a., twice the global growth rate

▪ NMC has c. 1,200 licensed beds in UAE with a population base of 9-10mn. This implies

potential for 3,000-4,000 beds in KSA on simple comparison

▪ KSA faces an estimated shortage of 50,000 beds by 2035, requiring substantial investment

▪ Median age of 29 years

▪ Healthy outlook for various

medical segments NMC focuses

on:

▪ Obstetrics and

Gynaecology; Paediatrics;

Fertility (IVF) and

Cosmetics

30% of the

pop’n <19 yrs

▪ Beds shortage in KSA estimated

at 15,000

▪ 30% of existing, overall beds in

the system blocked by LT care

patients

▪ Geriatrics continues to expand

at a rapid 7-8% CAGR

Considerable

demand for LT

care beds

▪ As with most GCC countries,

lifestyle disease is a major

problem in KSA

▪ Almost 70% of the population is

obese

▪ 30% of the population is

diabetic, or pre-diabetic

Prominence

of lifestyle

disease

Page 11: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

11

Continued roll-out of insurance coverage a significant potential

catalyst

11

Public sector 56%Private sector 44%

Stats Gov Est. Q2 2018*

population

33.4 m

Saudis

20.7

Expats

12.7

Saudis

5.0

Expats

10.2

Private Insurance Mandate

(Addressable Market)

15.2 m

Expats

8.2

Saudis

2.7Under insured

expats

1.2

Saudis

2.2

Public Coverage

18.2 m

Dependent of

expats & illegal

residents

0.9

Insured end Q2 ‘18

10.9 m

Under/Uninsured

4.3 m

Gov.

Employees

12.0

Retired

2.4Gov.

Employees

0.4Domestic

Helpers¹

2.1

Saudis

15.7 m

Expats

2.5 m

Unemployed

0.8

Others

0.5

Source: Stats.gov.sa, GOSI, Mol., CCHI, and Bupa Arabia estimates.

* Doesn’t include recent deportation of illegal expats

(1) Not under public coverage but also not under private insurance mandate

Saudis

15.7

Expats

2.5

Page 12: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

12

Agenda

12

1 Overview of the business

3 Transformational partnership with GOSI to form a new KSA healthcare champion

4 M&A: A vital part of the story

6 Financial outlook

7 Appendix A: A closer look at key assets

8 Appendix B: Snapshot of UAE healthcare market

5 Developing a dedicated International Patient Center

2 Understanding the Saudi opportunity better

Page 13: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

13

NMC and GOSI have entered a strategic partnership to create a

new national healthcare champion in KSA

13

Formation of a new and unique

national champion

#2 private healthcare operator in KSA

by beds capacity

Strong platform with pan KSA

presence

Wide ranging yet well defined

investment mandate

Strong synergy potential to support

sustainable value creation

1

2

3

4

5

Page 14: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

14

Formation of a new national champion

14

JV to be capitalized through:

▪ NMC to transfer its KSA assets

▪ GOSI/ Hassana to transfer their stake in CARE at

c.SAR70 per share

▪ NMC to fully consolidate the JV’s financials and retain

operational, Board and management control

▪ Transaction remains subject to regulatory approvals and

due-diligence

JV capitalization New structure

1

2

New JV

> 51% < 49%

38.9%majority

KSA Assets

New JV

38.9%

1

2At SAR70 /

share

KSA Assets

majority

Page 15: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

15

Addition of CARE to the existing portfolio: substantial growth

opportunity

15

Significant milestones achieved since inception which now includes 2 flagship hospitals

1967

Year incorporated

USD46m

2017 EBITDA

+7%

2013-17 EBITDA

CAGR

2013

Year listed

+10%

2013-17 Rev.

CAGR

USD380m

Total assets

USD667m

Market cap.(1)

c. 3,000

Total staff

Note: company information, Facstet. SAR to USD exchange rate: 0.2666

(1) As of 7 June, 2018 (closing share price: SAR55.8)

USD228m

2017 Revenue

1967 1991 2015

20%

2017 EBITDA

margin

0.5x

Leverage (2017

Net Debt/EBITDA)

10%

2017 Net profit

margin

RCH 330, CNH

495

Number of beds

2

Hospitals

1

Polyclinic

1

Mobile unit

Page 16: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

1616

Strategic geographic positioning across KSA

Chronic Care

Riyadh Care

Hospital330 beds

220 beds

Al Salam Medical

Group

As Salama

Hospital

100 beds

140 beds

NMC’s

hospitals

CARE’s

hospitals

Ha’il

Najran

Jeddah

Riyadh

Al Khobar

National Care

Hospital 495 beds

Al Rashid

Hospital64 beds

Al Qadhi

Specialty

140 beds

Page 17: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

17

664

788

825

998

1,020

1,328

1,489

c.1,850

Newly formed JV platform will be the second largest Saudi operator

by bed capacity in KSA

17

Source: companies website, AlpenCapital GCC Healthcare industry report (March 2018)

Notes: Market cap as of 6 June 2018

(1) Best estimate for the number of beds from publicly available sources which include the under construction Al-Habib Medical City, Al-Khobar Hospital and two hospitals in Jeddah

(2) No of beds does not include announced Greenfield project in Al Khobar by NMC

(3) Includes the under construction Mouwasat Hospital Al Khobar (220 beds)

(4) Includes the expansion of Dallah Hospital Al-Nakheel by 150 beds and the development of Namar Hospital (400 beds)

KSA

KSA

(1)

(3)

(4)

A combination of NMC’s KSA assets and CARE would immediately create one of the largest private

healthcare providers by beds capacity

(2)

10(1)

7

3

6(2)

2(3)

5

5

2

# of beds capacity # of hospitals

(2)

Beds capacity and number of hospitals Substantial growth expected in KSA bed numbers

~1,500

3,000

6,000

2018 3 - 5 years 5 - 10 years

Page 18: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

18

NMC is now in a position to replicate full continuum of care across

Saudi Arabia

18

Tertiary

Highly

specialised

Primary Care

Multi-specialty

UAE

Establishing an integrated

network across the full

continuum of care

UAE KSA

Page 19: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

19

Agenda

19

2

1

Understanding the Saudi opportunity better

Overview of the business

3 Transformational partnership with GOSI to form a new KSA healthcare champion

4 M&A: A vital part of the story

6 Financial outlook

7 Appendix A: A closer look at key assets

8 Appendix B: Snapshot of UAE healthcare market

5 Developing a dedicated International Patient Center

Page 20: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

20

10.2x

7.6x

9.6x

12.6x

11.1x

8.5x

12.9x 12.4x

17.4x

19.9x 19.9x

23.2x22.2x

21.0x

22.5x

33.9x

Feb-15 Apr-15 Apr-15 Jun-15 Nov-15 Aug-16 Dec-16 Jan-18

Snapshot of key acquisitions

20

57%

14%

4%

36%

16%

30%

14%

Price performance post-acquisition (+4 months)

Significant medium-term returns to NMC

shareholders from integration of acquisitions

Price m

ovem

ent

(fro

m p

re-a

nnouncem

ent clo

sin

g p

rice)

NMC undisturbed LTM EV/EBITDA (pre-acquisition)

LTM EV/EBITDA multiples paid: recent acquisitions (>USD25mn)

Demonstrated discipline in identifying and executing

immediately accretive acquisitions

Source: NMC, S&P Capital IQ

+24% on average

Page 21: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

21

90+30

+26

+140+17

+220 +5+26

Case study: Leveraging the long-term care acquisition

21

Evolution of long-term care beds

Source: NMC, S&P Capital IQ

▪ Fully acquired ProVita in June 2015

for a total consideration of US$ 161m

▪ 90 beds at time of acquisition

▪ Added 35 beds organically

▪ Cross-asset pollination:

▪ Added 52 and 17 LT care

beds in NMC Royal and Al

Zahra, respectively

▪ Dual benefit of enhancing

service offering and

improving margin profile

▪ Entered the Saudi market by

targeting the highly under-served LT-

care segment

▪ This route would not have

been possible without the

ProVita license and expertise

▪ Increase in number of beds from 90

to 554 done at an incremental cost of

only c. US$ 40m

No. of long-term care beds added to NMC network

90 120 146 286 303 523 528 554

No. of LT care

beds at

acquisition

Organic

expansion

H2 2015 H1 2016 H2 2017

Royal Hospital

additions

As-Salama

additions

Al Zahra

additions

Chronic Care

H1 2017

Total

beds

Organic

expansion

Royal

Hospital

additions

Page 22: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

22

Agenda

22

2

1

Understanding the Saudi opportunity better

Overview of the business

3 Transformational partnership with GOSI to form a new KSA healthcare champion

6 Financial outlook

7 Appendix A: A closer look at key assets

8 Appendix B: Snapshot of UAE healthcare market

5 Developing a dedicated International Patient Center

4 M&A: A vital part of the story

Page 23: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

23

NMC International Patient Development:

Capturing inbound & outbound medical tourism

23

▪ Dedicated referral clinics set up

within GCC facilities to refer

patients to the UK and Europe

▪ Working in conjunction with Dubai

Health Authority and Department

of Health – Abu Dhabi

▪ Develop customized packages for

patients from Middle East, India,

China and Africa for treatment

within UK and European facilities

▪ Rapid growth in medical tourists

Dedicated one-stop patient

services centre for NMC’s

international patients seeking

medical treatments outside

their home country

“A premature baby, who weighed less than an iPad Air at birth, has survived multiple

medical complications to go back home to her parents. Weighing just 390g when delivered

in the 23rd week of pregnancy at the NMC Royal Hospital, Dubai Investments Park, the

miracle baby now weighs 1.8kg and can breathe without assistance.

Probably the lightest to survive in the UAE, the baby girl has been named Angel.”

Page 24: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

24

Aspen Healthcare: An integral part of the IPC

24

9 facilities

of facilities

rated

outstanding or

good1

Outpatient &

diagnostic visits in

2017

223 beds

Inpatient & day

patient cases in

2017

19 theatres

Key highlights

300,000+43,000+

100%

Hospital locations

Parkside

Cancer Centre London

Claremont

Midland Eye

Nova

Chelmsford

Edinburgh

Holly

Highgate

Transfer of knowledge from Aspen to enhance NMC’s reputation as a

destination of choice for incoming tourists

Breadth and excellence of service Transfer of knowledge

Page 25: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

25

Agenda

25

1 Overview of the business

3 Transformational partnership with GOSI to form a new KSA healthcare champion

4 M&A: A vital part of the story

6 Financial outlook

7 Appendix A: A closer look at key assets

8 Appendix B: Snapshot of UAE healthcare market

5 Developing a dedicated International Patient Center

2 Understanding the Saudi opportunity better

Page 26: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

26

NMC’s strategy has delivered consistent long-term revenue and

EBITDA growth

26

Revenue (US$m)

339 387 444 490 551 644

881

1,221

2009 2010 2011 2012 2013 2014 2015 2016 2017

CAGR FY09-17: 21.4%

Growth

EBITDA (US$m)

42 56 71 80 93 103

150

246

2009 2010 2011 2012 2013 2014 2015 2016 2017

Growth

Margin

CAGR FY09-17: 30.5%

14.0% 14.8% 10.5% 12.4% 16.9% 36.8%

34.3% 25.0% 12.9% 16.7% 10.3% 46.7% 63.7%

12.4% 14.6% 15.9% 16.2% 16.9% 15.9% 17.1%

38.6%

20.2%

31.3%

44%

22.0%

353

1,603

Page 27: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

27

A snapshot of the business segments

1. Healthcare – Reported 2017 revenues up 41%, EBITDA up 31% to US$ 355.4m

2. Distribution – 2017 Revenues up 13%, SKU’s at 108.9k and EBITDA margin at 10.6%

3. Consolidated 2017 EBITDA at US$ 353.4m (+43.6% YoY), Net profit at US$ 209.2m (+38.2% YoY)1

27

880.9 1220.8 1,603.40

36.8%

38.6%31.3%

0%

10%

20%

30%

40%

50%

0

300

600

900

1,200

1,500

1,800

2015 2016 2017

Revenue Growth

Revenue US$m and annual growth

Source: NMC 2017 results presentation

1. 2015-2017 EBITDA corresponds to Profit from Operations before Depreciation, Amortisation, Impairment and Transaction Costs in the NMC annual reports

517.1 823.3 1,161.6

55.7%59.2%

41.1%

0%

20%

40%

60%

80%

0

500

1,000

1,500

2015 2016 2017

Revenue Growth

Healthcare revenue US$m and YoY growth

150.3

246.1

353.4

85.8

151.4

209.2

0

100

200

300

400

2015 2016 2017

EBITDA Net profit

EBITDA & Net profit US$m

393.4 431.9 486.8

16.1%

9.8%

12.7%

0%

5%

10%

15%

20%

0

200

400

600

2015 2016 2017

Revenue Growth

Distribution revenue US$m and YoY growth

43.5 47.1 51.5

11.1%10.9%

10.6%

8%

9%

10%

11%

0

10

20

30

40

50

60

2015 2016 2017

EBITDA EBITDA margin

Distribution EBITDA US$m and margin

3,211 4,320 5,767

34.3%34.5%

33.5%

33%

34%

35%

0

2,000

4,000

6,000

8,000

2015 2016 2017

Total patients Growth

Patients (‘000) and YoY Growth

137.0 241.1 355.4

26.5%29.3%

30.6%

0%

10%

20%

30%

40%

0

100

200

300

400

2015 2016 2017

EBITDA EBITDA margin

Healthcare EBITDA US$m and margin

33.3% 29.5% 30.6%

20%

25%

30%

35%

2015 2016 2017

Net working capital as % of sales

Scientific 11.1%

Homecare0.2%

Pharma 34.2%

Education4.6%

Veterinary0.4%

FMCG 35.3%

Food14.2%

Segment contribution 2017

Page 28: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

28

Key healthcare segment statistics

28

1,919 licensed beds

Healthcare verticals dominate revenue stream

Revenue/patient rising as complexity increasesSharp increase in operating beds capacity

Healthcare verticals continue to grow faster than Distribution (2017)

NMC Royal largest hospital by bed capacity

137 176 190

20%

28%

8%

0%

5%

10%

15%

20%

25%

30%

0

50

100

150

200

2015 2016 2017

Rev per pat Growth

537 679 1,365

87%

26%

101%

0%

20%

40%

60%

80%

100%

120%

-

200

400

600

800

1,000

1,200

1,400

1,600

2015 2016 2017

Operational beds Growth

316

220

156

140

140

127

125

125

116

106

102

100

86

60

834 487 206 114 8

50.6%

29.5%

12.5%6.9%

0.…

0%

10%

20%

30%

40%

50%

60%

0

200

400

600

800

1,000

Multispecialty Distribution Maternity &Fertility

LT &Homecare

O&M

Vertical revenues (US$mn) Share of revenues

Page 29: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

29

2018 guidance revised higher, 2019 to sustain growth momentum

Key figures2018: Upgraded guidance now in place

29

880.9 1,220.8 1,603.4

36.8%

38.6%

31.3%

0%

10%

20%

30%

40%

50%

0

300

600

900

1,200

1,500

1,800

2015 2016 2017

Revenue US$m and annual growth

Revenue Growth

150.3 246.1 353.4

17.1%

20.2%

22.0%

0%

5%

10%

15%

20%

25%

0

100

200

300

400

2015 2016 2017

EBITDA US$m and margin

EBITDA Margin

2019 outlook: Organic growth remains primary driver

▪ 2019E guidance:

▪ 22-24% YoY revenue growth

▪ 18-20% YoY EBITDA growth

▪ 2019 guidance does not include impact of IFRS 16

implementation or the anticipated financial consolidation of

National Medical Care

▪ Net debt-to-EBITDA projected at 2.2-2.4x at year end

▪ Growth capex of US$ 100m and maintenance capex to

sustain at 3% of revenues

▪ 2018E guidance:

▪ 24% YoY revenue growth (previously +22% YoY)

▪ EBITDA of around US$ 480m (previously US$ 465m)

▪ Organic growth projected at 15% YoY

▪ Receivable days continue to normalize in H2 18

▪ Pro-forma net debt-to-EBITDA projected at 2.8x at end-2018

▪ Balance sheets for all acquired entities will be fully

consolidated in 2018 and only partial income will be

recognized for the year

▪ On absolute basis year-end net debt-to-EBITDA to

stand around 3x

Page 30: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

30

Strong growth built within the system

Capex already incurred for upcoming beds*

30

Earnings uptrend to continue

25% EBITDA margin sustainable over long termBreakup of operational beds (2018E)

*: additional 300 beds under construction in Dubai

22%

25%

2 0 1 7 2 0 2 0 / 2 0 2 1

Group EBITDA margin

1,603

1,988

+22-24%

353 480

+18-20%

2017 2018E 2019E

Revenues (US$mn) EBITDA (US$mn)

537 679

1,365

1,935

2015 2016 2017 2018E

Operational beds

Breakup of operational beds

including Aspen

Breakup of operational beds

excluding Aspen

Mature

beds

57%

Beds in

ramp-up

phase

43%

Mature

beds

52%

Beds in

ramp-up

phase

48%

Page 31: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

31

Agenda

31

1 Overview of the business

3 Transformational partnership with GOSI to form a new KSA healthcare champion

4 M&A: A vital part of the story

6 Financial outlook

7 Appendix A: A closer look at key assets

8 Appendix B: Snapshot of UAE healthcare market

5 Developing a dedicated International Patient Center

2 Understanding the Saudi opportunity better

Page 32: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

32

Multispecialty Vertical:

The foundation of the healthcare business

32

Abu Dhabi Specialty: The original healthcare facility

US$575m

▪ Established in 1975 as a small pharmacy, with a clinic added in 1976

▪ 127-bed facility in the heart of Abu Dhabi island

▪ One of the largest top and bottom line contributors for NMC:

▪ 2017 revenues of over US$ 130m, serving over 1m patients p.a.

▪ Consistent EBITDA margin

▪ Sustaining 7-9% YoY revenue growth, despite maturity of the asset

▪ Increase in top line driven by:

▪ Annual price revisions

▪ Capacity expansions

▪ Introduction of more sophisticated specialisms

Al Ain Specialty: Key driver of intermediate growth

▪ Established in 2008, the facility is designed to cater to the greater

concentration of Emiratis within Al Ain’s population

▪ 125 licensed beds, 115 currently operational

▪ Al Ain Specialty has sustained over 20% revenue CAGR since its opening in

2008

▪ Al Ain Specialty’s top line growth is anticipated to moderate in the coming

years, but the facility will remain one of the key drivers of NMC’s revenue

and EBITDA growth over the near to medium term

Page 33: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

33

Multispecialty Vertical:

Dubai assets primed to capitalize on mandatory insurance rollout

33

Dubai Specialty: Leveraging off mandatory insurance in Dubai

US$575m

▪ 116-bed facility established in 2004

▪ Positive impact of introduction of mandatory insurance in Dubai already

visible in the form of improving patient footfall

▪ Witnessing double digit revenue and patient growth in past 3 years

▪ Given that the final phase of the mandatory insurance roll-out was

completed in March 2017, a material improvement in operations is

anticipated from 2018 onwards

▪ NMC owns the plot of land adjacent to Dubai Specialty Hospital, allowing for

doubling of capacity if sufficient patient demand is generated

DIP Hospital: Catering to “New Dubai”

▪ Located in Dubai Investment Park, the 86-bed facility is the only hospital

catering to a catchment of over 300,000 patients

▪ Only hospital in Southern Dubai with inpatient facilities

▪ Services offered include sophisticated specialisms such as:

▪ Cardiology

▪ Critical care medicine

▪ Neurology and

▪ Neonatology

▪ Similar to the case for Dubai Specialty, the DIP Hospital is anticipated to be

a key beneficiary of the roll-out of mandatory insurance in Dubai

Page 34: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

34

Multispecialty Vertical:

Major growth drivers of the future

34

Al Zahra Hospital: Completing the ‘hub & spoke’ model in Sharjah

US$575m

▪ NMC announced the US$ 560m acquisition of Al Zahra Hospital in

December 2016

▪ Widely recognized as the highest quality private sector hospital in Sharjah,

with over 35 years of operational experience

▪ Licensed capacity of 154 beds

▪ 17 long-term care beds introduced at the hospital; to be managed by

ProVita

▪ Ability to increase total number of beds to 200 without significant

capex

▪ Serves as a hub for NMC’s existing network of outpatient facilities in Sharjah

that cater to 800,000 patients per annum

▪ Focus on under-utilized specialities, such as cardiology, expected to

substantially improve revenue generation and margin profile

NMC Royal Hospital: Transformational impact on the healthcare portfolio

▪ Only private tertiary care hospital in UAE

▪ Licensed for 316 beds, with the potential to increase capacity to 400 beds

▪ Completed in late 2015, operational ramp-up progressing ahead of

expectations

▪ EBITDA breakeven achieved in less than 18 months versus original

guidance of 24 months

▪ A key beneficiary of the recent relaxation of regulations for Thiqa

cardholders, with Emiratis constituting over 40% of the patient base

▪ Expected to be primary top and bottom line growth driver for NMC from 2019

onwards and likely to become largest contributor by 2022

Page 35: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

35

Multispecialty Vertical:

Establishing a foothold in the lucrative Saudi market

35

Al Qadhi Specialty Hospital: Only private tertiary care facility in Najran

US$575m

▪ Only tertiary care facility in Najran, serving a population of over 500k

▪ The transaction was sourced and completed by NMC’s own team

▪ Strong business relationship with the original owner translated into

an attractive deal for NMC Health

▪ The facility recently signed a contract with the Saudi Arabian Society of

Metabolic and Bariatric Surgery for referral of patients

▪ Bariatric surgery represents addition of a value-add service to the

facility

▪ NMC’s team played an instrumental role in the introduction of this

service, reflecting rapid integration with the acquired entity

▪ Land and building owned by previous owner

▪ Long-term lease signed

▪ Owner also owns adjacent land, allowing further expansion

Al Rashid Hospital: First private hospital in Ha’il

▪ Established in 1991, Al Rashid was the first private hospital in Ha’il

▪ Serving a population of over 500k

▪ Benefits from a strong reputation and better geographic positioning

than competitors

▪ Ha’il remains underserved in terms of healthcare services

▪ Al Rashid currently offers primary and secondary care services

▪ New specialities to be added following the acquisition

▪ Transaction completed at one of the lowest multiples paid by NMC to date

▪ Land and building acquired as part of the transaction, with empty

adjacent land allowing further expansion

Page 36: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

36

Multispecialty Vertical:

Greater focus on specialisms in larger cities in KSA

36

Al Salam Medical Group: Entry into the largest healthcare market in KSA

US$575m

▪ Established in 1985, Al Salam Medical Group owns a 100-bed hospital and

2 polyclinics in Riyadh

▪ Served over 900k patients in 2016

▪ Transaction completed at less than 7x 2018E EV/EBITDA multiple

▪ Hospital and clinics offer a range of specialties, including cardiology and

paediatrics

▪ NMC to add a number of specialized services after the acquisition, including

long-term care, cosmetics and IVF

▪ Availability of vacant land adjacent to existing facility offers opportunity for

further growth

Page 37: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

37

Multispecialty Vertical:

Building a leading position in the Omani private healthcare space

37

Atlas Healthcare: The first extension of vertical outside UAE

US$575m

▪ Private healthcare sector still at a nascent stage in Oman

▪ With 102 beds, NMC’s facilities account for a 20% market share in

the private healthcare space

▪ Mandatory healthcare insurance to be rolled out in Oman from 2018

▪ Two facilities acquired from Atlas Healthcare, located in Ruwi and Ghubra,

respectively

▪ Both facilities have been upgraded and rebranded

▪ Focus on expansion of medical staff (particularly doctors) and introduction of

specialities to support improvement of operational performance

Page 38: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

38

Multispecialty Vertical:

Reinforcing the cosmetics and aesthetics business

38

CosmeSurge: A leader in a high growth market segment

US$575m

▪ Largest group of cosmetic surgeons, dermatologists and dentists in the GCC

▪ Enhances NMC’s cosmetic services portfolio

▪ Cosmetic and aesthetic services added to invasive cosmetic

procedures and complex surgeries already offered by NMC

▪ Transaction completed at an attractive 2018E EV/EBITDA multiple of 10.6x

▪ NMC managing CosmeSurge since September 2017 under O&M contract,

providing considerable insight into the business pre-acquisition

▪ Wide number of revenue and cost synergies identified prior to the

transaction

▪ Key areas in this regard include: cross-referral of patients, reduced

capex requirement from leveraging NMC’s existing capacity and cost

sharing of support services related to HR, IT and procurement

▪ CosmeSurge associated with attractive 31% EBITDA margin, with potential

for up to 400bps improvement on back of identified synergies

Page 39: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

39

Maternity & Fertility Vertical:

Second largest IVF player in the world

39

▪ NMC acquired 86.4% stake in Clinica Eugin for EUR 143mn in February

2015

▪ Ranked among top 3 fertility providers in Europe in terms of number of

cycles

▪ Clinica Eugin is a leading IVF centre of excellence, with world leading

technology and expertise

▪ Subsequent bolt-on acquisitions have expanded geographical and

knowledge base of the company

▪ Operating in Spain, Brazil, Columbia, Italy, Denmark, Sweden, Latvia

& Kenya

▪ Substantial knowledge transfer from Clinica Eugin to UAE, which is

transforming the IVF landscape in the country

Clinica Eugin: The start of the capability focused stage of growth strategy

US$575m

Fakih IVF: The undisputed market leader in UAE

▪ Solidified foothold in UAE fertility market by acquiring 51% stake in Fakih

IVF for US$ 189m in November 2015

▪ Outstanding 49% minority acquired in 2018, with Fakih IVF now a

wholly owned subsidiary of NMC

▪ Over 40% market share in UAE with more than 4,000 IVF cycles performed

each year

▪ Aggressive expansion underway:

▪ First IVF clinic established in Oman in 2018

▪ KSA represents a major growth market. Entry planned during 2018

Page 40: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

40

Maternity & Fertility Vertical:

Targeting a highly underserved segment of the market

40

▪ First private mother and child hospital in Abu Dhabi

▪ The 106-bed facility opened in July 2014 with only outpatient services

▪ Inpatient services introduced in July 2015, starting with 60

operational beds

▪ Brightpoint has consistently exceeded internal expectations and achieved

EBITDA breakeven earlier than original guidance provided by management

▪ Ability to cater to some of the most pronounced maternity-related

complications

▪ Premature births at as early as 24 weeks have been successfully

managed at NMC’s facilities

Brightpoint Royal Women’s Hospital: A first for the private sector in UAE

US$575m

Page 41: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

41

Long-Term & Home Care Vertical:

A vital component of NMC’s integrated healthcare offering

41

▪ NMC fully acquired ProVita in June 2015 for a total consideration of US$

161m

▪ Only two long-term care providers currently operating in the UAE

▪ A highly underserved market, with the UAE government spending

substantial amounts on Emirati patients in long-term care abroad

▪ 30 patients shifted from abroad to ProVita facilities already

▪ Number of beds increased from 90 at time of acquisition to 194

▪ 52 LT care beds added at NMC Royal Hospital

▪ 17 LT care beds added at Al Zahra

▪ 86% bed occupancy as at end-2017

ProVita: Pioneer in UAE long-term care market

US$575m

Chronic Care : Foray into the attractive Saudi market

▪ NMC entered the Saudi healthcare market in August 2016 through 1)

acquisition of a 70% stake in Al Salama Hospital in Al Khobar and 2)

investment in a start-up long-term care provider in Jeddah (Chronic Care)

▪ Chronic Care addresses the acute shortage of LT care beds in KSA

▪ Beds are made available to other healthcare operators on a “lease

plus” model to de-clog their ICU beds

▪ Retention payments made for usage of beds in the Jeddah facility

effectively remove receivables risk

Page 42: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

42

Aspen Healthcare: Adding value across multiple verticals

42

▪ Acquired 100% of Aspen Healthcare in 2018 at an Enterprise Value of GBP

10m, translating into 2018E EV/EBITDA of less than 2x

▪ Founded in 1998, Aspen Healthcare operates 9 facilities across the UK,

including 4 in the Greater London region.

▪ 7th largest player in the UK independent hospital market, accounting

for c. 2% market share

▪ With 223 beds, Aspen treats c. 350,000 patients per year

▪ Aspen offers strong expertise in Orthopaedics & Oncology, two of the most

underserved medical segments in the GCC

▪ Orthopaedics & Oncology account for c. 50% of Aspen’s revenues

▪ Aspen’s team has won several awards for deployment of innovative

medical treatments that can easily be adopted in the UAE

▪ Ideally positioned locations for introducing IVF services

▪ Significant opportunity for transferring knowledge across medical

procedures and diagnostics to UAE in particular and GCC in general

▪ Acquisition of Aspen will also allow NMC to capture outbound medical

tourists from the GCC, particularly for cases where adequate medical

procedures are not available in the region

▪ NMC can offer significant cost savings for governments and

individuals by offering pre and post care within its regional facilities

A key driver of NMC’s International Patient Centre

US$575m

Page 43: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

4343

▪ Over 40 years of experience has helped transform NMC Trading into one of

the top 3 distribution companies in the UAE

▪ Around 113,000 SKUs across several segments

▪ Exclusive wholesaler of mainly globally established and branded

healthcare products and equipment

▪ Additional distribution agreements, addition of agencies, customer tie-ups

and cost efficient operations contribute to driving performance

▪ Slower growth in the Distribution division, relative to the Healthcare business

resulting in declining contribution to top and bottom line

▪ High single digit revenue growth expected to sustain

▪ EBITDA margin stable around 9-10% mark

A high RoE business

US$575m

Distribution:

Exclusive tie-ups drive growth

Segment contribution (2017)

Scientific 11.1%

Homecare0.2%

Pharma 34.2%

Education4.6%

Veterinary0.4%

FMCG 35.3%

Food14.2%

Page 44: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

44

Agenda

44

2

1

Understanding the Saudi opportunity better

Overview of the business

3 Transformational partnership with GOSI to form a new KSA healthcare champion

4 M&A: A vital part of the story

6 Financial outlook

7 Appendix A: A closer look at key assets

8 Appendix B: Snapshot of UAE healthcare market

5 Developing a dedicated International Patient Center

Page 45: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

45

0

1

2

3

4

5

6

7

0 10 20 30 40 50 60

4.2%

3.5%

2.4%

1.5% 1.0%

0.8% 0.3%

UAE GCC Africa Oceania Asia Americas Europe

50%

95%

2006 - Pre 2014 - Post

Attractive dynamics in the UAE healthcare market

45

1. Strong Macro Indicators – ratings agencies estimate UAE GDP growth in 2017e of ~2.3%

High historic population growth1 High GDP per Capita2 (US$ ‘000)

2. Growing demand, spending and lagging capacity

3. Mandatory healthcare insurance: Abu Dhabi in 2007, Dubai started in 2014 and Sharjah is expected to be next

Abu Dhabi Est. % of population covered AD insurance categories7

Healthcare expenditure per capita4 (US$) Beds/GDP per capita5 ('000)

Source: (1) IHS Connect data, 2008-15 population growth CAGR. (2) As at 2016, Oxford Economics, GDP per capital, real US$, constant prices (3) Latest statistics based on Dubai Statistics Center Dubai Statistics Center, Dubai Courts

Department, Dubai Health Authority and Global Media Insight

Source: (4) WHO, BMI as at 2016. (5) As at 2015, GDP per capita sourced from government offices of statistics or central banks; (6) Latest statistics from WHO, BMI HAAD

Source: EIU, Booz & Co, IMF, HAAD, DHA, MOH, UAE Stats; (7) Abu Dhabi insurance categories based on 2016 HAAD payer members split

Medical staff/1,000 population6

66

52 46 42 41

36

21 17

Qatar US UK UAE Kuwait KSA OmanGermany

World Average: 1.2%

10,203

4,722

3,312

1,956 1,737 1,388 1,066

US UK Qatar UAE Kuwait KSAGermany

France Germany

USUK

UAE

Kuwait

BahrainKSA

Oman

Lebanon

Egypt

UAE est. population by Emirate3 (‘m)

4.10 3.33

1.53 0.95

0.67 0.38 0.19

AD Dubai Sharjah RAK Ajman Fujairah UAQ

NMC focus

UAE population

4.1m3.3m

2.5m

Abu Dhabi Dubai NorthernEmirates

Mostly

insured

Mostly

insuredMostly

uninsured

3.3

1.5 1.9

1.4 0.9

8.9

3.0 3.6

2.9 2.3

OECD UAE Dubai AD NE

Physicians Nurses

OECD Avg.

45%

36%

19%Basic

Enhanced

Thiqa

Page 46: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

46

Life-style diseases a major problem in UAE

▪ Non-communicable diseases responsible for largest

number of deaths among individuals below the age of 70

years in UAE

▪ Key concerns include cardiovascular, diabetes,

cancer and obesity

▪ WHO estimates 20% of UAE population has diabetes and

another 18% is at risk

▪ High genetic disorder incidence in UAE due to interfamily

marriages

▪ WHO estimates that, in 2012, average neo-natal

mortality rate was 5, while average mortality rate of

babies under 5 years of age was 8

High incidence of life-style related diseases

46

Over 70% deaths due to non-communicable disease*

Source: WHO

*: for population under 70 years of age

High prevalence of physical inactivity*

Source: WHO

*: for population under 70 years of age

Page 47: Investor Presentation - NMC...2018/11/05  · 2017 Group revenues: USD 1.6bn Operations across 17 countries Over 5.7 mn patients in 2017 2,186 licensed beds 2017 Group EBITDA: USD

47

UAE has a weight problem

47

Over 60% of UAE male population is overweight

Over 20% of UAE male population is obese… … while over 30% of female population is obese

… as is the case for female population

Source: WHO